Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies
Current Oncology · 04.03.2025 · 32 (3) · 149
DOI: 10.3390/curroncol32030149 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 04.03.2025. Verfasst von Ling Fan und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China. Hauptthemen laut MEDLINE: Hepatoblastoma, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific and Technological Innovation Major Base of Guangxi, Guangxi Science and Technology Major Program.
Abstract (Originalsprache)
Hepatoblastoma (HB) is the most common malignant liver tumor in children under five years of age. Although globally rare, it accounts for a large proportion of liver cancer in children and has poor survival rates in high-risk and metastatic cases. This review discusses the molecular mechanisms, diagnostic methods, and therapeutic strategies of HB. Mutations in the CTNNB1 gene and the activation of the Wnt/β-catenin pathway are essential genetic factors. Furthermore, genetic syndromes like Beckwith–Wiedemann syndrome (BWS) and Familial Adenomatous Polyposis (FAP) considerably heighten the risk of associated conditions. Additionally, epigenetic mechanisms, such as DNA methylation and the influence of non-coding RNAs (ncRNAs), are pivotal drivers of tumor development. Diagnostics include serum biomarkers, immunohistochemistry (IHC), and imaging techniques. Standard treatments are chemotherapy, surgical resection, and liver transplantation (LT). Emerging therapies like immunotherapy and targeted treatments offer hope against chemotherapy resistance. Future research will prioritize personalized medicine, novel biomarkers, and molecular-targeted therapies to improve survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
- National Center for International Research of Bio-Targeting Theranostics, Guangxi Medical University, Nanning 530021, China.
- Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning 530021, China.
- Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning 530021, China.
- Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning 530021, China.
- Center for Bioinformatics and Computational Biology, Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
Förderung
- Scientific and Technological Innovation Major Base of Guangxi
- Guangxi Science and Technology Major Program
Zitieren
APA
Fan, L., Na, J., Shi, T., & Liao, Y. (2025). Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies. Current Oncology, 32(3), 149. https://doi.org/10.3390/curroncol32030149
Vancouver
Fan L, Na J, Shi T, Liao Y. Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies. Current Oncology. 2025;32(3):149. doi:10.3390/curroncol32030149
BibTeX
@article{Fan2025,
author = {Fan, Ling and Na, Jintong and Shi, Tieliu and Liao, Yuan},
title = {Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {3},
pages = {149},
doi = {10.3390/curroncol32030149}
}
EUVIMED